Business · Companies · 1 hr ago
Challenger board declines to recommend TAL's $11.80-a-share offer
Challenger's board declined to recommend an offer from TAL Daiichi Life Australia for the Australian financial services company.
TAL proposed to buy the remaining Challenger shares for $11.80 each.
The proposal is indicative, non-binding and conditional, so it is not a confirmed takeover.
TAL is Challenger's largest shareholder and also a commercial partner.
Challenger's board says it wants a proposal that better reflects the company's value, and is open to further discussions with TAL.
There is no certainty TAL will make an improved or binding offer, and shareholders do not need to take action now.
Challenger's operations and plans are set to continue as usual, with further updates possible if talks progress.
Challenger's board declined to recommend TAL Daiichi Life Australia's indicative offer of $11.80 per share.
The offer is non-binding and conditional.
Challenger said it is open to further discussions with TAL about alternatives that may better reflect its value.
There is no certainty that an improved or binding offer will be made.
Shareholders do not need to take action until Challenger provides further updates.
- Who
- Challenger Ltd and TAL Daiichi Life Australia.
- What
- Challenger's board declined to recommend TAL's indicative offer of $11.80 per share for the remaining shares.
- When
- The update was published on 25 October 2026; Challenger first announced the offer on 19 October 2026.
- Where
- Not stated.
- Why
- The board's view is that the offer does not reflect Challenger's value and prospects.
This story does not have two clearly opposing sides.
Challenger made an initial announcement about TAL Daiichi Life Australia's indicative offer.
Challenger reported that its board had reviewed and declined to recommend the offer.
- Offer price
- $11.80 per share
- Offer status
- Indicative, non-binding and conditional
- Initial announcement
- 19 October 2026
- TAL's relationship with Challenger
- Largest shareholder and valued commercial partner
- Share price performance
- Challenger shares rose 35% over the past 12 months